Developing Topics.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 9 8 2024
pubmed: 9 8 2024
entrez: 9 8 2024
Statut: ppublish

Résumé

Hippocampal formation atrophy is a well-established imaging biomarker of several neurological diseases, including Alzheimer's disease, temporal lobe epilepsy, and schizophrenia. The hippocampus is divided into subfields that have different functions and vary in sensitivity to different diseases. This study investigates the potential interaction between COVID-19 and the various hippocampus subfields, which may shed light on the long-term neurological consequences of the virus. We obtained high-resolution T1-weighted (T1w) and T2-weighted (T2w) MRI images using 7T scanners located at three sites in two countries: Pittsburgh (n = 14) and Texas (San Antonio and Houston) (n = 40) in the USA, and Nottingham, UK (n = 33). We evaluated the hippocampus subfields using the ASHS package [1-3]. Imaging sets of 51 subjects with minimal or no manual segmentation corrections (Figures 1 and 2) were included in the analysis. We conducted T-tests with Bonferroni correction, adjusting for age and intracranial volume to identify the differences in hippocampus subfield volumes across groups. Participants who needed admission into the ICU due to Covid-19 showed a significantly lower (p-value = 0.0034) left CA1 volume compared to participants who did not require ICU (Figure 3). In addition, several other non-significant trends were observed. Our preliminary findings suggest that Covid-19 may impact the hippocampus, particularly in patients who required intensive care. However, the study - as of to date - has a small sample size and lacks a comparison group with patients who were admitted into ICU for acute illnesses other than Covid-19. Additionally, longitudinal data is needed to track the long-term effects of the disease on the hippocampal subfields. NIH R56AG074467, R01MH111265 and R01AG063525 References: 1. Berron et al. Neuroimage 2017 2. Yushkevich et al. Human Brain Mapping 2015 3. Santini et al. Neuroimage: clinical 2021.

Sections du résumé

BACKGROUND BACKGROUND
Hippocampal formation atrophy is a well-established imaging biomarker of several neurological diseases, including Alzheimer's disease, temporal lobe epilepsy, and schizophrenia. The hippocampus is divided into subfields that have different functions and vary in sensitivity to different diseases. This study investigates the potential interaction between COVID-19 and the various hippocampus subfields, which may shed light on the long-term neurological consequences of the virus.
METHOD METHODS
We obtained high-resolution T1-weighted (T1w) and T2-weighted (T2w) MRI images using 7T scanners located at three sites in two countries: Pittsburgh (n = 14) and Texas (San Antonio and Houston) (n = 40) in the USA, and Nottingham, UK (n = 33). We evaluated the hippocampus subfields using the ASHS package [1-3]. Imaging sets of 51 subjects with minimal or no manual segmentation corrections (Figures 1 and 2) were included in the analysis. We conducted T-tests with Bonferroni correction, adjusting for age and intracranial volume to identify the differences in hippocampus subfield volumes across groups.
RESULT RESULTS
Participants who needed admission into the ICU due to Covid-19 showed a significantly lower (p-value = 0.0034) left CA1 volume compared to participants who did not require ICU (Figure 3). In addition, several other non-significant trends were observed.
CONCLUSION CONCLUSIONS
Our preliminary findings suggest that Covid-19 may impact the hippocampus, particularly in patients who required intensive care. However, the study - as of to date - has a small sample size and lacks a comparison group with patients who were admitted into ICU for acute illnesses other than Covid-19. Additionally, longitudinal data is needed to track the long-term effects of the disease on the hippocampal subfields.
FUNDING BACKGROUND
NIH R56AG074467, R01MH111265 and R01AG063525 References: 1. Berron et al. Neuroimage 2017 2. Yushkevich et al. Human Brain Mapping 2015 3. Santini et al. Neuroimage: clinical 2021.

Identifiants

pubmed: 39120882
doi: 10.1002/alz.082651
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e082651

Informations de copyright

© 2023 the Alzheimer's Association.

Auteurs

Tales Santini (T)

University of Pittsburgh, Pittsburgh, PA, USA.

Salem Alkateeb (S)

University of Pittsburgh, Pittsburgh, PA, USA.

Jr-Jiun Liou (JJ)

University of Pittsburgh, Pittsburgh, PA, USA.

Jinghang Li (J)

University of Pittsburgh, Pittsburgh, PA, USA.

Oluwatobi F Adeyemi (OF)

Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom.

Gabriel A de Erausquin (GA)

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

Valentina R Garbarino (VR)

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

Monica Goss (M)

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.

Mohamad Habes (M)

University of Texas Health San Antonio, San Antonio, TX, USA.

Jayandra Jung Himali (JJ)

University of Texas Health San Antonio, San Antonio, TX, USA.

Christof Karmonik (C)

Houston Methodist Research Institute, Houston, TX, USA.

Karl Li (K)

University of Texas Health San Antonio, San Antonio, TX, USA.

Joseph C Masdeu (JC)

Houston Methodist Research Institute, Houston, TX, USA.

Rejani R Nair (RR)

Houston Methodist Research Institute, Houston, TX, USA.

Vibhuti N Patel (VN)

University of Texas Health San Antonio, San Antonio, TX, USA.

Beth E Snitz (BE)

University of Pittsburgh, Pittsburgh, PA, USA.

Richard Bowtell (R)

Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom.

Gowland Penny (G)

Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom.

Gustavo C Roman (GC)

Houston Methodist Research Institute, Houston, TX, USA.

Mary Ganguli (M)

University of Pittsburgh, Pittsburgh, PA, USA.

Farhaan S Vahidy (FS)

Houston Methodist Research Institute, Houston, TX, USA.

Timothy D Girard (TD)

University of Pittsburgh, Pittsburgh, PA, USA.

Heidi I L Jacobs (HIL)

Massachusetts General Hospital, Boston, MA, USA.

Akram A Hosseini (AA)

Nottingham University Hospitals NHS Trust, Queens Medical Center, Nottingham, United Kingdom.

Sudha Seshadri (S)

University of Texas Health San Antonio, San Antonio, TX, USA.

Tamer Ibrahim (T)

University of Pittsburgh, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH